These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31664064)

  • 1. Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis.
    Schmid A; Wolfensberger A; Nemeth J; Schreiber PW; Sax H; Kuster SP
    Sci Rep; 2019 Oct; 9(1):15290. PubMed ID: 31664064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
    Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
    Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal or intraventricular antimicrobial therapy for post-neurosurgical intracranial infection due to multidrug-resistant and extensively drug-resistant Gram-negative bacteria: A systematic review and meta-analysis.
    Hu Y; He W; Yao D; Dai H
    Int J Antimicrob Agents; 2019 Nov; 54(5):556-561. PubMed ID: 31398478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis.
    Li YY; Wang J; Wang R; Cai Y
    BMC Infect Dis; 2020 Jun; 20(1):408. PubMed ID: 32527246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.
    Zusman O; Altunin S; Koppel F; Dishon Benattar Y; Gedik H; Paul M
    J Antimicrob Chemother; 2017 Jan; 72(1):29-39. PubMed ID: 27624572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis.
    Onorato L; Di Caprio G; Signoriello S; Coppola N
    Int J Antimicrob Agents; 2019 Dec; 54(6):735-740. PubMed ID: 31479738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: A systematic review.
    Vardakas KZ; Athanassaki F; Pitiriga V; Falagas ME
    J Glob Antimicrob Resist; 2019 Jun; 17():250-259. PubMed ID: 30658202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High rate of extended-spectrum beta-lactamase-producing gram-negative infections and associated mortality in Ethiopia: a systematic review and meta-analysis.
    Tufa TB; Fuchs A; Tufa TB; Stötter L; Kaasch AJ; Feldt T; Häussinger D; Mackenzie CR
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):128. PubMed ID: 32771059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant profile and prevalence of extended spectrum β-lactamase and carbapenemase production in fermentative Gram-negative bacilli recovered from patients and specimens referred to National Reference Laboratory, Addis Ababa, Ethiopia.
    Beyene D; Bitew A; Fantew S; Mihret A; Evans M
    PLoS One; 2019; 14(9):e0222911. PubMed ID: 31553773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options.
    Jean SS; Lee WS; Lam C; Hsu CW; Chen RJ; Hsueh PR
    Future Microbiol; 2015; 10(3):407-25. PubMed ID: 25812463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria.
    Tängdén T
    Ups J Med Sci; 2014 May; 119(2):149-53. PubMed ID: 24666223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.
    Hawkey PM; Warren RE; Livermore DM; McNulty CAM; Enoch DA; Otter JA; Wilson APR
    J Antimicrob Chemother; 2018 Mar; 73(suppl_3):iii2-iii78. PubMed ID: 29514274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
    Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
    Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis.
    Chien HT; Lin YC; Sheu CC; Hsieh KP; Chang JS
    Int J Antimicrob Agents; 2020 Mar; 55(3):105889. PubMed ID: 31923573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies.
    Savoldi A; Carrara E; Piddock LJV; Franceschi F; Ellis S; Chiamenti M; Bragantini D; Righi E; Tacconelli E
    BMC Infect Dis; 2021 Jun; 21(1):545. PubMed ID: 34107899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration.
    Papadopoulos A; Ribera A; Mavrogenis AF; Rodriguez-Pardo D; Bonnet E; Salles MJ; Dolores Del Toro M; Nguyen S; Blanco-García A; Skaliczki G; Soriano A; Benito N; Petersdorf S; Pasticci MB; Tattevin P; Tufan ZK; Chan M; O'Connell N; Pantazis N; Kyprianou A; Pigrau C; Megaloikonomos PD; Senneville E; Ariza J; Papagelopoulos PJ; Giannitsioti E;
    Int J Antimicrob Agents; 2019 Mar; 53(3):294-301. PubMed ID: 30395988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.
    Cai B; Cai Y; Liew YX; Chua NG; Teo JQ; Lim TP; Kurup A; Ee PL; Tan TT; Lee W; Kwa AL
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4013-22. PubMed ID: 27090177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.